Endocrine therapy and endocrine resistant breast cancer

Share :
Published: 17 May 2012
Views: 4337
Rating:
Save
Prof Mitch Dowsett – The Institute for Cancer Research, London, UK

Prof Mitch Dowsett talks to ecancer about important papers presented at IMPAKT 2012 in Brussels, May 2012, on endocrine therapy, drug resistance, cell cycling and combination therapy.

 

Prof Dowsett discusses findings on everolimus, data from the BOLERO-2 study, which was presented by Prof Jose Baselga, and the outcomes from a phase 2 study involving CDK inhibitors.

 

Filming Supported by Amgen